Blood biomarkers as surrogate endpoints in Alzheimer’s disease research
Increased plasma levels of NfL or p-tau181 blood biomarkers were found to be associated with reduced brain volumes and/or declined cognitive outcomes, suggesting that these blood biomarkers may have a predictive role in AD trials.
Authors
- Charles Bernick (ORCID: https://orcid.org/0000-0003-4040-3587)
- Guoqiao Wang
- Guogen Shan (ORCID: https://orcid.org/0000-0001-8690-6599)
- Hui Li (ORCID: https://orcid.org/0000-0002-0406-9203)
- Yahui Zhang (ORCID: https://orcid.org/0000-0003-1965-6520)
Institutions
- Cleveland Clinic (US)
- Washington University in St. Louis (US)
- Lou Ruvo Brain Institute (US)
- University of Florida (US)
- Chongqing University of Technology (CN)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fnagi.2025.1576373
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- National Institutes of Health